Advanced Filters
noise

Charlestown, Massachusetts Clinical Trials

A listing of Charlestown, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,872 clinical trials

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, …

18 years of age All Phase 1
R Rita Mehta, MD

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the …

18 years of age All Phase 2
C Christopher Bositis, MD

Pre-exposure Prophylaxis (PrEP) for Health

This randomized controlled trial will test the efficacy of "PrEP for Health," a behavioral intervention to improve the use of antiretroviral pre-exposure prophylaxis (PrEP) among at-risk people who inject drugs (PWID) in two syringe service program (SSP) settings in Lawrence and Boston/Cambridge, Massachusetts. The investigators will equally randomize 200 PWID …

18 years of age All Phase N/A
N Nancy K Latham, PhD

NAD Augmentation in Diabetes Kidney Disease

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

60 years of age All Phase 2
S Site Public Contact

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.

18 years of age All Phase 1/2
M Melissa A St Hilaire, Ph.D.

Menstrual-phase-dependent Differences in Response to Sleep Loss

This study is designed to assess how healthy premenopausal women respond to different patterns of sleep loss at different times in the menstrual cycle.

18 - 35 years of age Female Phase N/A
M Michael Parsons, PhD

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.

60 years of age Female Phase N/A
E Eva Wu

Gamma-Music Based Intervention for Mild Alzheimer's Disease

The study will test and refine a novel brain-stimulation tool using gamma-frequency lights coupled with self-selected music for a gamma-music-based intervention for participants with mild Alzheimer's Disease. Results will yield a gamma-stimulation protocol that reliably influences brain activity (Aim 1), is adaptive, motivating and rewarding to use (Aim 2), and …

50 - 95 years of age All Phase N/A
M Mina Sedrak

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

70 years of age All Phase 2
C Carrie Smith

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.

18 - 85 years of age All Phase 1

Simplify language using AI